Phathom Pharmaceuticals, Inc. Stock News

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episodic heartburn in non-erosive gastroesophageal reflu

Announcing topline data from its PHALCON-NERD trial for vonoprazan, Phathom Pharmaceuticals (PHAT) said that the experimental on-demand therapy for episodic heartburn met the main goal…

FLORHAM PARK, N.J., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported positive topline results from PHALCON-NERD, a Phase 2 study evaluating three dose levels of vonoprazan (10 mg, 20 mg, and 40 mg) as an on-demand therapy for relief of episodic heartburn in subjects with non-erosive gastroesophageal reflux disease (NERD). In this double-blind, placebo-controlled study, all three vonoprazan dose levels successfully met the primary endpoint and were statistically significant (p<0.0001) when compared to placebo.

Phathom Pharmaceuticals: Undiscovered Gem

NeuBase Therapeutics (NBSE) appoints Todd P. Branning as the company''s new chief financial officer. Prior to joining NeuBase, Branning served as CFO of Phathom Pharmaceuticals (PHAT)…

Phathom Pharmaceuticals Inc (PHAT) shares closed today at 0.5% above its 52 week low of $16.61, giving the company a market cap of $524M. The stock is currently down 15.1% year-to-date, down 52.7% over the past 12 months, and down 32.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 8.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 852.4% The company's stock price performance over the past 12 months lags the peer average by 75.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Bank of America Corp DE decreased its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 2.2% during the second quarter, HoldingsChannel reports. The institutional investor owned 63,544 shares of the companys stock after selling 1,460 shares during the period. Bank of America Corp DEs holdings in Phathom Pharmaceuticals were worth $2,152,000 at the end []

Phathom Pharmaceuticals Inc (PHAT) shares closed 3.9% lower than its previous 52 week low, giving the company a market cap of $622M. The stock is currently down 40.4% year-to-date, down 54.1% over the past 12 months, and down 19.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 59.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 28.3% The company's stock price performance over the past 12 months lags the peer average by 97.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Phathom Pharmaceuticals Inc (PHAT) shares closed today at 1.5% above its 52 week low of $19.51, giving the company a market cap of $653M. The stock is currently down 37.4% year-to-date, down 51.2% over the past 12 months, and down 15.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 39.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 22.2% The company's stock price performance over the past 12 months lags the peer average by 111.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have been assigned a consensus rating of Buy from the six analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average 12 month []

State Street Corp raised its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 56.7% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 340,303 shares of the companys stock after purchasing an additional 123,105 shares during the period. State Street Corp owned 1.09% []

FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will

FLORHAM PARK, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tr

Phathom Pharmaceuticals (NASDAQ:PHAT) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued to clients and investors on Saturday, Zacks.com reports. According to Zacks, Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The companys []

FLORHAM PARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea